Register
Page 13 of 14 FirstFirst ... 311121314 LastLast
Results 121 to 130 of 131
  1. #121
    Biệt Thự
    Join Date
    Dec 2014
    Posts
    555
    Quote Originally Posted by hoanghac View Post

    ...
    Bác sĩ Stella Immanuel khi phát biểu đã khó giấu được tình cảm kích động, bà nói sau khi sử dụng HCQ hoặc Zinc, bà đã điều trị được cho hơn 350 bệnh nhân. “Sau khi họ sử dụng HCQ đều được bình phục, không có một ca tử vong nào”.

    Bà Stella Immanuel phê bình quan điểm của chuyên gia thuộc Viện Y tế Quốc gia Mỹ (NIH) và Trung tâm Kiểm soát Bệnh tật Mỹ (CDC) rằng “nghiên cứu đối với HCQ vẫn chưa chín muồi”. “Trong lúc có lượng lớn bệnh nhân tử vong, họ lại kiên trì muốn làm nghiên cứu mù quáng? Đây là điều vô đạo đức!”.

    Bà Stella Immanuel và đội ngũ của mình đều đang sử dụng HCQ để dự phòng virus. Hiện tại, trong số họ không có ai lây nhiễm virus, mặc dù mỗi ngày họ đều có thể tiếp xúc với nơi có virus, ví dụ như bệnh nhân sử dụng máy thở.

    https://trithucvn.net/the-gioi/thuoc...loroquine.html
    Mới nhớ ra bác Hạc Vàng có đăng bài về côn trùng Cồ-Vịt-19 này trong đó nhắc đến một bác sĩ thiên tài có thể trị con trùng này bằng thuốc sốt rét hiệu nghiệm vô song là bác sĩ Stella Immanuel trên đây. Với thành tích trị được cho hơn 350 bệnh nhân bằng thuốc sốt rét như thế này mà tất cả đều bình phục chứ không có một ca tử vong nào thì còn bác sĩ nào khác sánh kịp. Hơn nữa cả thuốc sốt rét lẫn thành tích của bà bác sĩ này cũng đã được tổng thống tán thưởng và đề cao cũng như khuyến khích mọi người nên dùng thuốc này và truyền bá video của bà bác sĩ này để dẫn chứng khả năng siêu... nhiên của thuốc và bác sĩ Immanuel. Sao nhân viên Tòa Bạch Ốc quên mất hay sao mà cứ để cho các bác sĩ linh tinh khác dùng các loại đuôi gà (cocktail) thuốc vô danh tiểu tốt nào đâu mà không cấp tốc liên lạc ngay với vị bác sĩ này và xuất kho ngay một mớ thuốc sốt rét đã đặt mua sẵn từ lâu rồi để điều trị liền cho tổng thống? Thánh Thất Trắng làm việc tắc trách quá!

  2. #122
    I can't breathe. ốc's Avatar
    Join Date
    Sep 2011
    Location
    Ốcland
    Posts
    6,583
    Chắc Trâm hy sinh để dành thuốc sốt rét cho hạng tép riu giòi bọ xài.

  3. #123
    Biệt Thự Triển's Avatar
    Join Date
    Sep 2011
    Posts
    22,803

    Nghe Lính Đại Ca đồn là ai đi lính chị y tá cũng
    bắt hả họng nuốt thuốc chống sốt rét. Vậy là
    hồi đó Trâm chứng thực là trốn quân dịch rồi chớ
    cúm chai na mà cũng bị lây sao?
    http://dtphorum.com/pr4/signaturepics/sigpic726_7.gif

  4. #124
    I can't breathe. ốc's Avatar
    Join Date
    Sep 2011
    Location
    Ốcland
    Posts
    6,583
    Thuốc cúm giã tật, sự thật mất lòng:

    Covid drug given to Trump developed using cells derived from aborted fetus
    https://www.theguardian.com/world/20...-from-abortion

    One of the drugs taken by Donald Trump that he has touted as a potential “cure” for coronavirus was developed using human cells originally obtained from an elective abortion, a practice repeatedly denounced by the president and many of his supporters.

    The drug is a monoclonal antibody cocktail developed by Regeneron. The president received an 8-gram infusion under a “compassionate use” exemption when he was hospitalized over the weekend after testing positive for Covid-19. There is no cure for Covid-19, and the drug is not approved.

    The stem cells used to develop the drug are known as HEK-293T cells, a line of cells used in laboratories. The cells were originally derived from an embryonic kidney after an elective abortion performed in the Netherlands in the 1970s.
    Good job, doc!


  5. #125
    Biệt Thự Triển's Avatar
    Join Date
    Sep 2011
    Posts
    22,803
    Quote Originally Posted by ốc View Post
    obtained from an elective abortion

    À há, nghe đồn đảng cộng hòa gì đó chống phá thai.
    Pure cannibalism.
    http://dtphorum.com/pr4/signaturepics/sigpic726_7.gif

  6. #126
    Biệt Thự Triển's Avatar
    Join Date
    Sep 2011
    Posts
    22,803



    J&J pauses COVID-19 vaccine trials due to unexplained illness in participant

    By Reuters Staff


    (Reuters) - Johnson & Johnson JNJ.N said on Monday it had temporarily paused its COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest profile efforts to contain the global pandemic.

    The participant's illness is being reviewed and evaluated by an independent data and safety monitoring board as well as the company's clinical and safety physicians, the company said here in a statement.

    J&J, which reports quarterly financial results on Tuesday morning, said that such pauses are normal in big trials, which can include tens of thousands of people. It said the “study pause” in giving doses of the vaccine candidate was different from a “regulatory hold” required by health authorities. The current case is a pause.

    However, J&J's move follows a similar one by AstraZeneca Plc. In September, AstraZeneca AZN.L paused late-stage trials of its experimental coronavirus vaccine, developed with the University of Oxford, due to an unexplained illness in a UK study participant.

    While trials in the UK, Brazil, South Africa and India have resumed, the U.S. trial is still on hold pending a regulatory review.

    Dr. William Schaffner, a professor of infectious diseases at the Vanderbilt University School of Medicine, said by email that “Everybody is on the alert because of what happened with AstraZeneca,” adding that it could take a week to gather information.

    “It would have to be a serious adverse event. If it was something like prostate cancer, uncontrolled diabetes or a heart attack - they wouldn’t stop it for any of those reasons. This is likely to be a neurological event,” he said.

    Last month, J&J said its experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, following which the company kicked off a final 60,000-person trial, whose results had been expected by the end of this year or early 2021.

    Johnson & Johnson declined to elaborate about the illness due to privacy concerns. It did say that some participants in studies get placebos, and it was not always clear whether a person suffering a serious adverse event in a clinical trial received a placebo or the treatment.

    Stat News reported here the pause earlier in the day citing a document sent to outside researchers, which stated that a "pausing rule" had been met, the online system used to enroll patients in the study had been closed and the data and safety monitoring board would be convened.

    Reporting by Ayanti Bera in Bengaluru, Deena Beasley in Los Angeles and Peter Henderson in Oakland; Editing by Rashmi Aich


    /* src.: https://www.reuters.com/article/us-h...-idUSKBN26Y01Q


    http://dtphorum.com/pr4/signaturepics/sigpic726_7.gif

  7. #127
    Biệt Thự Triển's Avatar
    Join Date
    Sep 2011
    Posts
    22,803

    Miễn nhiễm?



    Covid reinfection: Man gets Covid twice and second hit 'more severe'

    By James Gallagher
    Health and science correspondent



    A man in the United States has caught Covid twice, with the second infection becoming far more dangerous than the first, doctors report.

    The 25-year-old needed hospital treatment after his lungs could not get enough oxygen into his body.

    Reinfections remain rare and he has now recovered.

    But the study in the Lancet Infectious Diseases raises questions about how much immunity can be built up to the virus.

    The man from Nevada had no known health problems or immune defects that would make him particularly vulnerable to Covid.

    What happened when

    • 25 March - First wave of symptoms, including sore throat, cough, headache, nausea and diarrhoea
    • 18 April - He tests positive for the first time
    • 27 April - Initial symptoms fully resolve
    • 9 and 26 May - He tests negative for the virus on two occasions
    • 28 May - He develops symptoms again, this time including fever, headache, dizziness, cough, nausea and diarrhoea
    • 5 June - He tests positive for the second time, and is hypoxic (low blood oxygen) with shortness of breath



    Scientists say the patient caught coronavirus twice, rather than the original infection becoming dormant and then bouncing back. A comparison of the genetic codes of the virus taken during each bout of symptoms showed they were too distinct to be caused by the same infection.

    "Our findings signal that a previous infection may not necessarily protect against future infection," said Dr Mark Pandori, from the University of Nevada.

    "The possibility of reinfections could have significant implications for our understanding of Covid-19 immunity."

    He said even people who have recovered should continue to follow guidelines around social distancing, face masks and hand washing.

    Scientists are still grappling with the thorny issue of coronavirus and immunity.

    Does everyone become immune? Even people with very mild symptoms? How long does any protection last?

    These are important questions for understanding how the virus will affect us long-term and may have implications for vaccines and ideas such as herd immunity.

    So far, reinfection seems to be rare - there have been only a few examples out of more than 37 million confirmed cases.

    Reports in Hong Kong, Belgium and the Netherlands said they were no more serious than the first. One in Ecuador mirrored the US case in being more severe, but did not need hospital treatment.

    However, it is still early into the pandemic, and the history of other types of coronavirus means protection is expected to wane.

    As countries endure a second wave of the virus, we may start to get clearer answers.

    It had been assumed that a second round of Covid would be milder, as the body would have learned to fight the virus the first time around.

    It is still unclear why the Nevada patient became more severely ill the second time. One idea is he may have been exposed to a bigger initial dose of the virus.

    It also remains possible that the initial immune response made the second infection worse. This has been documented with diseases like dengue fever, where antibodies made in response to one strain of dengue virus cause problems if infected by another strain.

    Prof Paul Hunter, from the University of East Anglia, said the study was "very concerning" because of the small gap between the two infections, and the severity of the second.

    "Given the fact that to date over 37 million people have had the infection, we would have expected to have heard of many more incidents if such very early reinfections with severe illness were common.

    "It is too early to say for certain what the implications of these findings are for any immunisation programme. But these findings reinforce the point that we still do not know enough about the immune response to this infection."


    /* src.: https://www.bbc.com/news/health-54512034

    http://dtphorum.com/pr4/signaturepics/sigpic726_7.gif

  8. #128
    Biệt Thự Triển's Avatar
    Join Date
    Sep 2011
    Posts
    22,803



    Coronavirus: Remdesivir is no miracle cure


    While Remdesivir reduces the mortality rate and the duration of the illness COVID-19, it's no magic remedy. Now a prematurely leaked WHO study confirms earlier research results.



    Soon after the very first cases of coronavirus infections in China, attentions turned to Remdesivir as a potential drug to treat the illness. Remdesivir was originally developed to treat Ebola infections, but it also showed effectiveness against SARS and MERS coronaviruses in laboratory tests. The new SARS-CoV-2 is considered a variant of the 2002 SARS pathogen.

    The drug was developed by the US pharmaceutical company Gilead Sciences as GS-5734. At the outset of the pandemic, it was not approved by any country.

    It has since been used in the context of an Emergency Use Authorization (EUA), as well as in the context of scientific studies in numerous countries. Gilead Sciences gave the drug the brand name Veklury in Autumn 2020.

    After an initial clinical trial in the US showed positive results in May 2020, the US Food and Drug Administration (FDA) granted the EUA. Since then, Remdesivir was able to be used in hospitals for the treatment of individual patients with the lung disease COVID-19 outside clinical trials.

    The World Health Organization (WHO) published a non-peer-reviewed preprint study on MedRxiv on October 15, 2020 showing that Remdesivir barely reduces the mortality rate of COVID-19 patients. The study is a result of the so-called 'SOLIDARITY Trial' in which the data of 11,266 patients was evaluated.

    Gilead Sciences in a statement argued that by having the study published as a preprint, "the data from this open-label global trial have not undergone the rigorous review required to allow for constructive scientific discussion."

    In the same statement, the companyreferenced another study with 1062 volunteers, that was recently published in the New England Journal of Medicine (NEJM), which showed that Remdesivir could reduce the average healing time from 15 to 10 days.

    Gilead Sciences filed an application for regular approval of the drug with the FDA on August 7, 2020. It has not yet been approved.

    How does Remdisivir work?

    The antiviral effect of Remdesivir derives from its function as a so-called nucleotide analogue. The active substance inhibits the RNA polymerase (RdRp) of viruses such as Ebola and MERS because its structure is similar to RNA building blocks. During virus replication, these are erroneously incorporated into the genetic strands of the new virus copies. Truly functional new viruses cannot be created in this way.

    Although Remdesivir did not prove to be really effective in fighting Ebola, cell culture experiments and initial experiments on macaques showed that it had a promising effect against the coronaviruses SARS and MERS-CoV, which are closely related to SARS-CoV-2.

    Early clinical trials with Remdesivir carried out in the US and China were intended to show if the drug also helps against COVID-19.

    White House celebrates positive effects

    Initial positive results of an early randomized clinical trial in the US were announced on April 29, 2020 directly from the White House in Washington DC. Speaking about Remdesivir at a press conference with US President Donald Trump at the White House, the director of the National Institute for Allergy and Infectious Diseases (NIAID), Anthony Fauci, then stated: "This will be the standard of care."

    A total of 1,063 patients with varying degrees of severity of the disease had taken part in the NIAID-funded study, the "Adaptive COVID-19 Treatment Trial"'Adaptive COVID-19 Treatment Trial' and were treated with Remdesivir or a placebo for 10 days.

    In such a randomized double-blind study, neither the treating physicians nor the patients know who is injected daily with the active substance and who receives a placebo. This is to prevent any expectations of the drug from possibly distorting the actual results.

    The results were similar, albeit not quite as clear as those from the new NEJM study. According to NIAID, preliminary results suggested that COVID-19 patients receiving Remdesivir had, on average, a 31% faster recovery time than patients given the placebo. Patients that received Remdesivir had an average recovery time of 11 days and patients receiving the placebo had an average recovery time of 15 days.

    The mortality rate in the Remdesivir-treated group was 8% compared to 11.6% in the placebo group.

    Trials ended prematurely

    Those responsible for the trials then considered them sufficient. The National Institutes of Health in the US said that the results were meaningful enough. At a meeting of the Data Safety Monitoring Board (DSMB) on April 27, 2020 it was decided to terminate the study prematurely.

    In parallel with the successful reports from Washington, there were additional reports from China, where Remdesivir was first tested for its efficacy in randomized clinical trials in Wuhan on patients in intensive care units suffering from severe cases of COVID-19.

    Eventually, however, Wuhan lacked the necessary patients because of a sharp decline in new infections, and that study was also terminated prematurely, according to a report in The Lancet.

    What do the results mean?

    Both the early two studies, as well as the more recent published and leaked studies, seem to point to the same conclusion: The active substance Remdesivir has clearly proven to be moderately effective. It reduces the death rate slightly but not significantly and it reduces the duration of the disease by a few days.

    Although this is encouraging, it is far from being the resounding success that many had hoped for from what was described as the most promising drug candidate to date.

    German infectious disease expert, Gerd Fätkenheuer, professor of medicine at the University Hospital Cologne, had expected a quick approval for Remdesivir after the publication of the NIAID study in May. He was leading a clinical trial of Remdesivir with patients in Germany.

    "For patients with a severe form of this disease, this study gives hope that they will be able to recover from the infection more quickly and safely," he said. "The yardstick for the effectiveness of potential other drugs will, in the future, be Remdesivir."

    "The results of the large-scale SOLIDARITY study from the WHO with 11,266 patients included worldwide are not entirely unexpected, but no less disappointing" Clemens Wendtner, chief physician for infectiology and tropical medicine at the Munich Municipal Hospital said.

    "Despite the limitation that no detailed data are available on the preprint server to date and a peer review process is still pending, it can be stated that the study has failed to meet its primary endpoint: None of the four drugs tested — Remdesivir, hydroxychloroquine, Lopinar/Ritonavir, and IFN-ß1a - are capable of reducing COVID-19 mortality in symptomatic patients requiring hospital treatment," said Wendtler about the most recent study.


    /* src.: https://www.dw.com/en/coronavirus-re...ure/a-53326847
    http://dtphorum.com/pr4/signaturepics/sigpic726_7.gif

  9. #129
    Biệt Thự Triển's Avatar
    Join Date
    Sep 2011
    Posts
    22,803



    Bắt đầu ngày mai chắc cổ phiếu
    hãng này tuột giá hơn 1,8%. Tin này
    bay ra làm nhiều người sẽ không dám đi
    chích ngừa khi có thuốc. Bây giờ
    nhiều người mới hiểu là giai đoạn
    thử nghiệm thứ ba quan trọng như
    thế nào.





    AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue


    By Eduardo Simões, Ludwig Burger

    SAO PAULO/FRANKFURT (Reuters) - Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca AZN.L and Oxford University had died but added that the trial would continue.

    Oxford confirmed the plan to keep testing, saying in a statement that after careful assessment “there have been no concerns about safety of the clinical trial.”

    AstraZeneca declined to comment immediately.

    A source familiar with the matter told Reuters the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine, suggesting the person was part of the control group that was given a meningitis jab.

    The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, said an independent review committee had also recommended the trial continue. The university earlier confirmed the volunteer was Brazilian but gave no further personal details.

    “Everything is proceeding as expected, without any record of serious vaccine-related complications involving any of the participating volunteers,” the Brazilian university said in a statement.

    So far, 8,000 of the planned 10,000 volunteers in the trial have been recruited and given the first dose in six cities in Brazil, and many have already received the second shot, said a university spokesman.

    CNN Brasil reported that the volunteer was a 28-year-old man who lived in Rio de Janeiro and died from COVID-19 complications.

    Anvisa provided no further details, citing medical confidentiality of those involved in trials.

    AstraZeneca shares fell 1.8%.

    Brazil's federal government has plans to purchase the UK vaccine and produce it at biomedical research center FioCruz in Rio de Janeiro, while a competing vaccine from China's Sinovac Biotech Ltd SVA.O is being tested by Sao Paulo state's research center Butantan Institute.

    Brazil’s President Jair Bolsonaro said on Wednesday the federal government will not buy the Sinovac vaccine.

    Brazil has the second deadliest outbreak of the coronavirus, after the United States, with more than 154,000 killed. It has the third largest number of cases, with more than 5.2 million infected, after the United States and India.

    /* src.: https://www.reuters.com/article/us-h...-idUSKBN2762MO
    http://dtphorum.com/pr4/signaturepics/sigpic726_7.gif

  10. #130
    Biệt Thự Triển's Avatar
    Join Date
    Sep 2011
    Posts
    22,803


    Không có gì gọi là chắc chắn. Nhưng cũng đừng đánh mất hi vọng.



    Antibodies 'fall rapidly after infection'

    By James Gallagher
    Health and science correspondent



    Levels of protective antibodies in people wane "quite rapidly" after coronavirus infection, say researchers.


    Antibodies are a key part of our immune defences and stop the virus from getting inside the body's cells.

    The Imperial College London team found the number of people testing positive for antibodies has fallen by 26% between June and September.

    They say immunity appears to be fading and there is a risk of catching the virus multiple times.

    More than 350,000 people in England have taken an antibody test as part of the REACT-2 study so far.

    In the first round of testing, at the end of June and the beginning of July, about 60 in 1,000 people had detectable antibodies.

    But in the latest set of tests, in September, only 44 per 1,000 people were positive.

    It suggests the number of people with antibodies fell by more than a quarter between summer and autumn.

    "Immunity is waning quite rapidly, we're only three months after our first [round of tests] and we're already showing a 26% decline in antibodies," said Prof Helen Ward, one of the researchers.

    The fall was greater in those over 65, compared with younger age groups, and in those without symptoms compared with those with full-blown Covid-19.

    The number of healthcare workers with antibodies remained relatively high, which the researchers suggest may be due to regular exposure to the virus.

    Antibodies stick to the surface of the coronavirus to stop it invading our body's cells, and attract the rest of the immune system.

    Exactly what the antibody drop means for immunity is still uncertain. There are other parts of the immune system, such as T-cells, which may also play a role.

    However, the researchers warn antibodies tend to be highly predictive of who is protected.

    Prof Wendy Barclay said: "We can see the antibodies and we can see them declining and we know antibodies on their own are quite protective.

    "On the balance of evidence, I would say it would look as if immunity declines away at the same rate as antibodies decline away, and that this is an indication of waning immunity."

    There are four other human coronaviruses, which we catch multiple times in our lives. They cause common cold symptoms and we can be reinfected every six to 12 months.

    There have been very few confirmed cases of people getting Covid twice. However, the researchers warn this may be due to immunity only just starting to fade since the peak infection rates of March and April.

    The hope is the second infection will be milder than the first, even if immunity does decline, as the body should have an "immune memory" of the first encounter and know how to fight back.

    The researchers say their findings do not scupper hopes of a vaccine, which may prove more effective than a real infection.

    One of the researchers, Prof Graham Cooke, said: "The big picture is after the first wave, the great majority of the country didn't have evidence of protective immunity.

    "The need for a vaccine is still very large, the data doesn't change that.
    "


    /* src.: https://www.bbc.com/news/health-54696873



    http://dtphorum.com/pr4/signaturepics/sigpic726_7.gif

 

 

Similar Threads

  1. Coronavirus COVID-19 - WATCH AT YOUR OWN RISKS
    By TLNVN in forum Thời Sự Trong Ngày
    Replies: 57
    Last Post: 05-04-2020, 11:38 AM
  2. Replies: 1
    Last Post: 02-29-2020, 08:04 PM
  3. Replies: 0
    Last Post: 10-23-2019, 03:20 AM
  4. Replies: 5
    Last Post: 12-18-2011, 12:10 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  
All times are GMT -7. The time now is 05:06 PM.
Powered by vBulletin® Version 4.2.5
Copyright © 2020 vBulletin Solutions Inc. All rights reserved.
Forum Modifications By Marco Mamdouh